Slow-release insulin in cystic fibrosis patients with glucose intolerance: a randomized clinical trial

Pediatric Diabetes, 04/27/2012

Minicucci L et al. – Glargine treatment was well accepted and tolerated. No real efficacy in improving clinical and glycometabolic conditions was demonstrated. Further studies are necessary to test glargine at higher dosage and for a longer follow–up period.


  • In this phase 3 multicenter, controlled, two-arm, randomized clinical study, glargine was administered up to a dosage of 0.15 U/kg/die for a period of 18 months.
  • Primary endpoint was the improvement of nutritional status [body mass index (BMI) Z score], while glucose tolerance [hemoglobin A1c (HbA1C) and respiratory function (FEV1 predicted] improvement were the secondary endpoints.


  • Thirty-four subjects (18 in the glargine arm and 16 in the control arm) were evaluated.
  • Adherence to insulin treatment was excellent.
  • No significant adverse events were reported.
  • There were no significant differences in BMI, HbA1C and FEV1 values between the two groups nor within groups, except for HbA1C improvement in the glargine arm at month +18 (p = 0.04).

Print Article Summary Cat 2 CME Report